{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:24:20Z","timestamp":1765887860979,"version":"3.37.3"},"reference-count":53,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Different therapeutic agents are currently available for the treatment of RRMM. By performing an NMA, we identified a lenalidomide-dexamethasone + mAb regimen as the most active therapeutic option in this setting.<\/jats:p>","DOI":"10.1182\/bloodadvances.2016003905","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T20:40:27Z","timestamp":1488228027000},"page":"455-466","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients"],"prefix":"10.1182","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1522-4504","authenticated-orcid":false,"given":"Cirino","family":"Botta","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Ciliberto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Staropoli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Cuc\u00e8","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Galeano","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Magna Graecia University, Salvatore Venuta University Campus, Catanzaro, Italy; and"},{"name":"Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2017,2,27]]},"reference":[{"issue":"5","key":"2019111619231069800_B1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2019111619231069800_B2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2013.293","article-title":"International Myeloma Working Group recommendations for global myeloma care","volume":"28","author":"Ludwig","year":"2014","journal-title":"Leukemia"},{"issue":"20","key":"2019111619231069800_B3","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111619231069800_B4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2013.099358","article-title":"European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma","volume":"99","author":"Engelhardt","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2019111619231069800_B5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-016-0286-x","article-title":"Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory\/relapsed multiple myeloma","volume":"9","author":"Liu","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2019111619231069800_B6","doi-asserted-by":"crossref","first-page":"27361","DOI":"10.1038\/srep27361","article-title":"Efficacy and safety of panobinostat in relapsed or\/and refractory multiple myeloma: meta analyses of clinical trials and systematic review","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"issue":"24","key":"2019111619231069800_B7","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"2019111619231069800_B8","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"2019111619231069800_B9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111619231069800_B10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111619231069800_B11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","article-title":"Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study","volume":"88","author":"Hjorth","year":"2012","journal-title":"Eur J Haematol"},{"key":"2019111619231069800_B12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"6","key":"2019111619231069800_B13","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4161\/cbt.28557","article-title":"Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials","volume":"15","author":"Staropoli","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2019111619231069800_B14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0895-4356(92)90085-2","article-title":"Incorporating variations in the quality of individual randomized trials into meta-analysis","volume":"45","author":"Detsky","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"7109","key":"2019111619231069800_B15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"2019111619231069800_B16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"50","key":"2019111619231069800_B17","doi-asserted-by":"crossref","first-page":"82741","DOI":"10.18632\/oncotarget.12633","article-title":"Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation","volume":"7","author":"Staropoli","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2019111619231069800_B18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pan.2016.01.003","article-title":"Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer","volume":"16","author":"Ciliberto","year":"2016","journal-title":"Pancreatology"},{"issue":"3","key":"2019111619231069800_B19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejca.2012.08.019","article-title":"Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials","volume":"49","author":"Ciliberto","year":"2013","journal-title":"Eur J Cancer"},{"key":"2019111619231069800_B20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"2019111619231069800_B21","doi-asserted-by":"crossref","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"2019111619231069800_B22","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2019111619231069800_B23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"issue":"20","key":"2019111619231069800_B24","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","article-title":"Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR\/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111619231069800_B25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111619231069800_B26","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111619231069800_B27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111619231069800_B28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2012","journal-title":"Haematologica"},{"issue":"24","key":"2019111619231069800_B29","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111619231069800_B30","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"2019111619231069800_B31","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111619231069800_B32","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111619231069800_B33","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111619231069800_B34","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111619231069800_B35","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2019111619231069800_B36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111619231069800_B37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/cncr.27745","article-title":"Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma","volume":"119","author":"White","year":"2013","journal-title":"Cancer"},{"issue":"13","key":"2019111619231069800_B38","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/cncr.30026","article-title":"Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"122","author":"Orlowski","year":"2016","journal-title":"Cancer"},{"issue":"25","key":"2019111619231069800_B39","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111619231069800_B40","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"5","key":"2019111619231069800_B41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"17","key":"2019111619231069800_B42","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111619231069800_B43","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1471-2288-13-147","article-title":"Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making","volume":"13","author":"Cope","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"2019111619231069800_B44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00262-015-1711-7","article-title":"Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients","volume":"64","author":"Cusi","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2019111619231069800_B45","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/CJI.0000000000000004","article-title":"Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial","volume":"37","author":"Correale","year":"2014","journal-title":"J Immunother"},{"issue":"4","key":"2019111619231069800_B46","doi-asserted-by":"crossref","first-page":"e1101205","DOI":"10.1080\/2162402X.2015.1101205","article-title":"Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients","volume":"5","author":"Correale","year":"2015","journal-title":"OncoImmunology"},{"issue":"10027","key":"2019111619231069800_B47","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"2019111619231069800_B48","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111619231069800_B49","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1517\/14712598.2013.799130","article-title":"Immunologic microenvironment and personalized treatment in multiple myeloma","volume":"13","author":"Rossi","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"2019111619231069800_B50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fonc.2014.00348","article-title":"Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities","volume":"4","author":"Botta","year":"2014","journal-title":"Front Oncol"},{"issue":"12","key":"2019111619231069800_B51","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1038\/bcj.2016.118","article-title":"A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival","volume":"6","author":"Botta","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111619231069800_B52","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14728214.2016.1186644","article-title":"Emerging antibodies for the treatment of multiple myeloma","volume":"21","author":"Zagouri","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"journal-title":"Blood","article-title":"Targeting the PD-1\/PD-L1 axis in multiple myeloma: a dream or a reality?","author":"Rosenblatt","key":"2019111619231069800_B53"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/7\/455\/878183\/advances003905.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/7\/455\/878183\/advances003905.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T19:23:37Z","timestamp":1573932217000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/7\/455\/16025\/Network-metaanalysis-of-randomized-trials-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,27]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2016003905","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2017,2,27]]}}}